| From: jmhollen | 6/29/2006 4:18:21 PM | | | | | | (eMail): MN1.com Press Conference for GenoMed
ST. LOUIS, MO, Jun 29, 2006 – GenoMed, Inc. (PINKSHEETS: GMED) will conduct a live press conference on www.MN1.com at 9:30am Central Time Friday, June 30th, 2006. Interested parties may go to www.MN1.com and download the free player enabling them to listen in for management's review of operations and discussion of future prospects. This live broadcast is available to anyone at any computer connected to the Internet. This should prove to be an eye-opening and enriching experience for all of those associated with GenoMed (PINKSHEETS: GMED).
About MN1.com
MN1.com is the only online destination that brings real microcap news to investors and features live interaction with companies from the Bulletin Board, Pink Sheets, and Amex. Featuring Live Press Conferences, All-Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items, and "The MicroBlog," MN1.com gives microcap investors the information source necessary to trade in the markets. MN1.com boasts being the largest true news company reporting on microcap traded stocks.
About GenoMed
GenoMed (PINKSHEETS: GMED) is a St. Louis-based Next Generation Disease Management company that uses genomics to improve patient outcomes. Besides kidney disease, GenoMed has novel approaches to many additional diseases, including a general viral antidote. Anyone can download GenoMed's protocol for avian influenza or West Nile virus from GenoMed's website, www.genomed.com, at any time of day or night.
CONTACT: David Moskowitz MD
GenoMed, Inc.
www.genomed.com
Tel. 314-983-9938
SOURCE: GenoMed
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (302) | 8/4/2006 10:26:58 PM | | From: Tadsamillionaire | | | | GenoMed's First Horse Recovers Quickly from Presumed West Nile Virus Encephalitis
ST. LOUIS, July 31 /PRNewswire-FirstCall/ -- GenoMed (OTC: GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the first horse in its expanded trial for West Nile virus encephalitis recovered completely within 24 hours after starting GenoMed's treatment.
Four days ago, a horse owner in Idaho contacted GenoMed to say that her horse had begun moving much more slowly, and that the veterinarian was treating it for West Nile virus encephalitis. Only two days before, another of her horses had to be put down for presumed West Nile virus encephalitis because it could no longer lift its head and eat.
Within 24 hours of starting GenoMed's treatment, the horse was 'quick on its feet' and appeared fully recovered. The horse's prompt recovery from West Nile virus encephalitis was like that GenoMed has observed since 2003 in people, and since 2004 in birds.
GenoMed's protocol uses a class of already existing blood pressure pills to block the brain inflammation caused by West Nile virus. This disease mechanism appears to be shared by all vertebrates infected with most viruses, leading GenoMed to believe it may have found a safe, general viral antidote. For this reason, GenoMed's approach was included in the language of the Project BioShield II Act of 2005, introduced by Senators Lieberman, Hatch, and Brownback. This bill has not yet been debated in the US Senate.
GenoMed's treatment success rate for WNV encephalitis in people is currently 86% (19 of 22 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'We're delighted that our anti-viral approach appears to work in yet another species. The veterinary community already treats West Nile virus encephalitis as an excessive inflammation of the brain, and is embracing our approach far more readily than the public health community. As a result, I'm afraid that we may save more horses than people this year.' |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/8/2006 11:19:30 AM | | | | | | GenoMed's West Nile Virus Trial Endorsed by Emergency Medicine Authority
Neal Handly, MD
tel. 610.563.0664
nh28@drexel.edu
David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—August 8, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced the endorsement of its trial for West Nile virus encephalitis by an authority in Emergency Medicine, Dr. Neal Handly.
Dr. Handly is Associate Director of Research for the Department of Emergency Medicine at Drexel University College of Medicine and a Fellow of the American Academy of Emergency Medicine. Dr. Handly chairs the Academy's Subcommittee on Information Technology.
Dr. Handly said, "GenoMed's protocol is extremely exciting, since we're in the grip of another West Nile epidemic this summer without any known treatment. The Emergency Room is where these cases are seen first. It makes sense to have the ER be a partner in a clinical trial."
Dr. Handly continued, "Dr. Moskowitz uses safe medicines already familiar to every ER physician. What makes his approach appealing is the possibility that it may work for many viruses, including avian influenza and bioterrorist viral attacks. These last two scenarios are of special concern to the Emergency Medicine community."
About Dr. Handly
Dr. Neal Handly is an Assistant Professor in the Department of Emergency Medicine at Drexel University College of Medicine in Philadelphia, PA. He was consulted to create a state-of-the-art ER this summer in Beirut, Lebanon but has been prevented from doing so by the current hostilities.
About GenoMed
Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, www.genomed.com, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/8/2006 12:41:30 PM | | | | | | Update on GenoMed's First Horse with Presumed West Nile Virus Encephalitis
"Frog," the first horse treated with GenoMed's protocol for West Nile virus encephalitis, is about 90% recovered after 2 weeks.
His story was first aired on the 5.30 pm news yesterday on KBCI TV Channel 2, Boise, Idaho, and can be accessed at: kbcitv.com
Sincerely yours,
Dave Moskowitz MD FACP
CEO & Chief Medical Officer
GenoMed, Inc.
genomed.com
tel. 314.983.9933
dwmoskowitz@genomed.com
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/16/2006 11:34:33 AM | | | | | | GenoMed's Treatment Speeds Up Texas Policeman's Recovery from West Nile Paralysis
David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com
ST. LOUIS—August 16, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced that a Texas policeman with paralysis from the waist down due to West Nile virus has accelerated his recovery since starting GenoMed's treatment last week.
The patient contracted West Nile virus encephalitis a month ago. On Monday of that week he was fine, but by Friday, his legs were so weak that he could only get around by crawling. Although he was hospitalized for the next two weeks, he showed little improvement and had become discouraged.
Last week, on Thursday afternoon, August 10th, the patient and his physician began GenoMed's protocol. Two days later, on Saturday, August 12th, the patient walked with assistance for 100 steps, compared to only 18 steps on Friday, the day before. Yesterday, Tuesday, August 15th, the patient could easily move the toes in his right foot for the first time, as well as begin to move his right foot sideways.
Said GenoMed's CEO and Chief Medical Officer, David Moskowitz MD, FACP, "This patient's accelerated recovery from West Nile virus reinforces the idea that our treatment should be used early in all patients suspected of West Nile virus encephalitis. It is possible that he might not have progressed to paralysis if his physician had started him on our treatment during the very first week of symptoms."
Added Dr. Moskowitz, "Getting the word out about our treatment may literally make the difference between life and death, or in this case a quick recovery versus prolonged paralysis."
About GenoMed
Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 87% treatment success rate (20 of 23 patients). The first 8 patients were published two years ago in a peer-reviewed medical journal, and GenoMed still has the only published treatment for West Nile virus encephalitis in the medical literature. This summer GenoMed extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, www.genomed.com, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/17/2006 10:52:27 AM | | | | | | GenoMed's Second Horse Recovers Quickly from Presumed West Nile Virus Encephalitis
David W. Moskowitz MD - GenoMed - St. Louis, Missouri - Tel. 314.983.9933 - dwmoskowitz@genomed.com
Randy Bean DVM - Owyhee Veterinary Clinic - Homedale, Idaho - Tel. 208-337-4677
ST. LOUIS—August 17, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the second horse in its expanded trial for West Nile virus encephalitis recovered completely within 72 hours after starting GenoMed's treatment.
On Saturday afternoon this past weekend, a horse owner in Idaho telephoned Dr. Randy Bean to say that his horse could no longer walk straight. The horse had not been vaccinated for West Nile virus, and the diagnosis was presumed West Nile virus encephalitis. The usual treatment for a horse with WNV costs about $700, and includes antiserum and intravenous dexamethasone. The owner didn't want to spend that much money on his horse. Dr. Bean, who had recently treated another horse with GenoMed's approach, encouraged the owner not to just let his horse die, but to try GenoMed's treatment, which costs $10 a day.
Within 72 hours, the horse was fully recovered.
West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. Dr. Bean feels that GenoMed's treatment made the difference, and is now calling for a wider trial of GenoMed's approach in horses.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "I'm delighted that Dr. Bean has managed to cure a second horse with presumed WNV using our approach. I'm hoping our treatment finally gets a fair trial this year."
GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.
About GenoMed
Anyone can download the human protocol for West Nile virus for free from GenoMed's website, www.genomed.com, at any time. Horse owners are encouraged to contact Dr. Moskowitz or Dr. Bean directly (see contact information above) to discuss specific medications and dosing.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/21/2006 10:10:06 AM | | | | | | GenoMed's Third Horse with Presumed West Nile Virus Encephalitis Is Better in 24 Hours
David W. Moskowitz MD
GenoMed
St. Louis, Missouri
Tel. 314.983.9938
dwmoskowitz@genomed.com
ST. LOUIS—August 21, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the third horse in its expanded trial for West Nile virus encephalitis recovered markedly within 24 hours after starting GenoMed's treatment.
On Thursday afternoon last week, a horse owner in Fresno, California telephoned GenoMed to say that her horse could no longer walk straight and was falling down. The horse had not been vaccinated for West Nile virus, and the diagnosis by the veterinarian was presumed West Nile virus encephalitis.
Within 24 hours of the first dose of GenoMed's treatment, the horse was chasing other horses away from his food, which they had been eating while he was sick.
West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. As with people, recovery from viral encephalitis usually takes at least a week. Recovery within 24 hours, like GenoMed's three horses and most of GenoMed's human patients, is extremely unusual.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "It's always thrilling to see a clinical trial showing great results. Every trial is really just a gamble. Fortunately, this one seems to be continuing to pay off. All our evidence for the past four years, in humans, birds, and now horses, has been extremely positive."
GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.
About GenoMed
Anyone can download the human protocol for West Nile virus for free from GenoMed's website, www.genomed.com, at any time. Horse owners are encouraged to contact Dr. Moskowitz directly (see contact information above) to discuss dosing.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/29/2006 9:31:06 AM | | | | | | GenoMed Cleared by Indian Government to Distribute Healthcare to India
Contact:
David Moskowitz MD
CEO, GenoMed, Inc.
St. Louis, Missouri
www.genomed.com
Tel. 314-983-9933
Email: dwmoskowitz@genomed.com
Ms. Sujata Mital
Director, Sumit Biosciences Pvt Ltd.
Mumbai, India
www.sumitbiomedical.com
Email: sumit_exports@yahoo.com
ST. LOUIS, August 29, 2006 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management (DM) company whose business is public health™, announced today that it has obtained clearance, through their Indian distributor Sumit Biosciences Pvt Ltd, from the Indian Government to market its Next Generation DM™ product in India.
The cost is under US $150 per patient per year. Since the per capita income in India is around $600 a year, GenoMed's Next Generation DM™ service is well within the reach of the average Indian citizen.
Sumit Biosciences Pvt Ltd is currently enlisting physicians at the King Edward Memorial Hospital in Mumbai to offer GenoMed's protocols to their patients. Mumbai, formerly called Bombay, is the fourth largest city in the world, with 12 million inhabitants.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "The US and Europe have been completely uninterested in our published methods for preventing kidney dialysis and slowing down emphysema. The $25 billion a year that the US spends on dialysis may actually serve as a perverse financial disincentive not to eliminate the industry. India spends nothing on dialysis, so nobody there has a financial stake in preserving the dialysis industry."
Added Dr. Moskowitz, "It's as if the Directors of the TB sanitaria in the US ignored streptomycin in 1950 to save their jobs. It's a shame that the taxpayers of the US and Europe are paying for genomics-based medicine, but citizens of developing countries like India are the only ones using it."
About GenoMed™
GenoMed is the only biotechnology company serious about both lowering healthcare costs and improving patient outcomes. It is leading the clinical revolution made possible by knowing which genes cause which diseases. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company is offering its Healthchip®, on a research basis only, to predict breast, colon, lung, ovarian, pancreatic, and prostate cancer in Caucasians. And GenoMed is in the process of creating a virtual pharmaceutical company to develop new drugs for the hundreds of cancer chemotherapy targets it has discovered, where no drug yet exists.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Tadsamillionaire | 9/1/2006 4:51:12 PM | | | | | | West Nile virus warnings posted in Livermore and Pleasanton
By Meera Pal
CONTRA COSTA TIMES
Signs have been posted in Livermore parks and at the Alameda County Fairgrounds in Pleasanton, warning residents that several birds, squirrels and mosquitoes were found infected with West Nile virus.
While no human cases of West Nile virus have been reported in Alameda County, officials from the county's Mosquito Abatement District say it is a matter of time.
"We are going to see a human case pretty soon in Tri-Valley," said John Rusmisel, district manager. "These cases are more concentrated."
The district was first notified of a dead bird in southwest Livermore on Aug. 6. Lab results came back positive for West Nile virus. Since then, the district has collected five infected birds and one squirrel and identified three positive mosquito pools in southwest Livermore.
This morning, warning signs were posted at El Padro and Max Baer parks in Livermore and in the general vicinity.
The abatement district is concentrating on an area bordered by Isabel Avenue on the west side, Highway 84 on the east, and El Caminito and Stanley Boulevard on the north in Livermore and at the fairgrounds in Pleasanton.
The district is treating and keeping an eye on catch basins, storm drains and swimming pools in that area, Rusimelhe said.
According to the district's Web site, "mosquitoes need stagnant water in order to lay their eggs . . . if it can hold water for more than a few days, it can breed mosquitoes."
So far this year, Rusmisel said the district has positively identified 17 birds with the virus in Alameda County, compared to last year's total of 48. This year, they have marked seven positive mosquito pools, two at the fairgrounds in Pleasanton.
"This is the first time we have put up signs" anywhere in the county, Rusmisel said.
It is the concentration of infected mosquito pools in the area that cause concern, he said. Birds can fly in from other locations. Infected mosquitoes make it easier to transfer the disease to humans.
PREVENT MOSQUITO BITES
According to the Center for Disease Control and Prevention, about 20 percent of people who become infected with the virus will develop West Nile fever. Symptoms include fever, headache, tiredness, and body aches. The illness can last anywhere between a few days to several weeks.
"People describe it as the worst headache they've ever had," Rusmisel said.
The signs are not intended to alarm anyone, but to remind Tri-Valley residents that the threat of West Nile virus is real.
mercurynews.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 9/11/2006 6:07:06 PM | | | | | | GenoMed: Cure for Sickle Cell Pain
Monday September 11, 9:30 am ET
ST. LOUIS, Sept. 11 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED - News), the Next Generation Disease Management company whose business is public health(TM), announced today that it has submitted a case report of a sickle cell patient whose pain disappeared with GenoMed's treatment approach, only to recur when it was stopped.
The patient is a middle-aged African American woman who for years required multiple pain pills every day to tolerate the pain of her sickle cell disease. Since beginning GenoMed's trial on Dec. 22, 2005, she experienced no pain until her trial medication ran out on February 6, 2006. Said her physician, who is lead author on the case report, "Prior to this experiment, for over two years, there has not been more than a day, at least during the winter months, when she has not required some Vicodin."
Her pain ceased within a few days of resuming GenoMed's treatment in February. In June, her physician intentionally stopped GenoMed's treatment. Off GenoMed's treatment, the patient's pain recurred within a week. When she again resumed GenoMed's treatment, her pain again stopped within a few days. She has been pain-free on GenoMed's treatment for three months now, since June.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Although only a single patient, she satisfied Koch's postulates, which constitute a rigorous clinical test. As long as the patient was using our treatment, her pain was gone. On two occasions, one accidental and one deliberate, our treatment was stopped. On both occasions her pain recurred promptly, only to disappear quickly after treatment was resumed. It doesn't get much more convincing than this."
Added Dr. Moskowitz, "Ever since Max Perutz showed the molecular defect in sickle cell hemoglobin in 1946, for which he won the Nobel Prize, sickle cell disease has been a sober reminder that knowing the molecular cause of a disease is still a far cry from curing it."
Dr. Moskowitz ended by saying, "We're eager to acquire more sickle cell patients to see if what has cured this patient's pain will work for every patient. It's fitting that our potential cure comes during America's Sickle Cell Awareness and Pain Awareness Month."
About GenoMed
GenoMed owns patents pending for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including sickle cell disease. To enroll in GenoMed's sickle cell disease trial, please contact Dr. Moskowitz at dwmoskowitz@genomed.com .
Source: GenoMed |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
